{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05884775",
            "orgStudyIdInfo": {
                "id": "23-00608"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "Novel Digital Patient-Reported Outcomes Tool for Diabetes Management",
            "officialTitle": "iMatter2: An Artificial Intelligence (AI)-Driven Approach to Supercharge a Novel Digital Patient-reported Outcomes Tool for Diabetes Management",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "novel-digital-patient-reported-outcomes-tool-for-diabetes-management"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2025-02-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-10-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-23",
            "studyFirstSubmitQcDate": "2023-05-23",
            "studyFirstPostDateStruct": {
                "date": "2023-06-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Agency for Healthcare Research and Quality (AHRQ)",
                    "class": "FED"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D)."
        },
        "conditionsModule": {
            "conditions": [
                "Type 2 Diabetes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 353,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "iMatter2",
                    "type": "EXPERIMENTAL",
                    "description": "All the patients within a primary care provider (PCP) randomized to the intervention will receive iMatter2.",
                    "interventionNames": [
                        "Other: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool"
                    ]
                },
                {
                    "label": "Usual Care (UC)",
                    "type": "NO_INTERVENTION",
                    "description": "All patients within PCPs randomized to UC will receive standard Type 2 diabetes (T2D) care by their PCP."
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool",
                    "description": "Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.",
                    "armGroupLabels": [
                        "iMatter2"
                    ],
                    "otherNames": [
                        "iMatter2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Hemoglobin A1C (HbA1c)",
                    "description": "HbA1c will be extracted from home A1c kits.",
                    "timeFrame": "Baseline, Month 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Patients Eligible for Participation in Trial who Enroll",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Percentage of PCP Practices Eligible for Participation in Trial that Enroll",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Percentage of Providers who View PRO Reports",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Percentage of Patients who Respond to PRO Text Messages",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Percentage of Patients who View PRO Interactive Dashboard",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Mean Number of EHR Reports Viewed by Providers",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Total Number of EHR Reports Viewed by Providers",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Percentage of PRO Messages Responded To by Patients",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Mean Number of PRO Messages Responded To by Patients",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Total Number of PRO Messages Responded To by Patients",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Mean Number of Reports Viewed by Patients via PRO Interactive Dashboard",
                    "timeFrame": "Up to Month 12"
                },
                {
                    "measure": "Total Number of Reports Viewed by Patients via PRO Interactive Dashboard",
                    "timeFrame": "Up to Month 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPCP Group:\n\n* Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and\n* Provide care to at least five patients with a diagnosis of T2D\n\nPatient Group:\n\n* Have a diagnosis of T2D for \u22656 months;\n* Have uncontrolled T2D defined as HbA1c \\>7% documented in the EHR on at least two vi its in the past year;\n* Fluency in English or Spanish;\n* Be willing to send/receive text messages; and\n* Be \\> 18 years of age.\n\nExclusion Criteria:\n\nPatient Group:\n\n* Refuse or are unable to provide informed consent;\n* Have acute renal failure, end stage renal disease (ESRD) or evidence of dialysis, renal transplantation, or other ESRD-related services documented in the EHR;\n* Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR);\n* Are pregnant or planning to become pregnant within 12 months;\n* Currently participate in another T2D study; or\n* Plan to discontinue care at the clinic within the next 12 months.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Antoinette Schoenthaler",
                    "role": "CONTACT",
                    "phone": "6465013434",
                    "email": "Antoinette.schoenthaler@nyulangone.org"
                },
                {
                    "name": "Ronaldo Patino Flores",
                    "role": "CONTACT",
                    "email": "ronaldo.patinoflores@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Antoinette Schoenthaler",
                    "affiliation": "NYU Langone Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "NYU Langone Health",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "IPD collected in this study will be available only to:\n\n* The research team, including the Principal Investigator, study coordinators, and personnel responsible for the support or oversight of the study\n* The study sponsor: The Agency for Healthcare Research and Quality"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "relevance": "LOW"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}